On June 12, 2026 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) reported results from the Phase III part of the ESLIM-02 study of sovleplenib in patients with warm antibody autoimmune hemolytic anemia ("wAIHA") in China were presented on Thursday, June 11, 2026 during the European Hematology Association (EHA) (Free EHA Whitepaper) ("EHA") Congress in Stockholm, Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Supported by data from the ESLIM-02 study, a New Drug Application ("NDA") for sovleplenib for the treatment of adult patients with wAIHA who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration ("NMPA") in April 2026. The NMPA granted Breakthrough Therapy Designation to sovleplenib for the treatment of wAIHA in March 2026. The ESLIM-02 presentation was selected for the official EHA (Free EHA Whitepaper) Press Program.

Professor Bing Han of Peking Union Medical College Hospital, and co-leading Principal Investigator of the ESLIM-02 study, said: "The wAIHA treatment paradigm has remained stagnant for decades, with patients often trapped in a cycle of high-dose steroids and frequent relapses. The ESLIM-02 data are transformative as they demonstrate that targeting the Syk pathway can achieve both rapid and durable control of hemolysis. We are particularly encouraged by the robust data across all patient subgroups, regardless of their prior treatments. Sovleplenib’s ability to significantly reduce the need for rescue therapies and blood transfusions represents a major step forward in restoring the quality of life for these patients."

ESLIM-02 is a randomized, double blind, placebo-controlled China Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to at least one prior line of standard treatment (NCT05535933). Results from the Phase II part of the study were published in The Lancet Haematology in January 2025. In Phase III part of the study, 90 patients were randomized 1:1 to receive either sovleplenib (n=44) or placebo (n=46) at a dose of 300 mg once daily for 24 weeks.

The study met its primary endpoint, with sovleplenib demonstrating a significantly higher durable response rate during weeks 5–24 compared to placebo (66% vs 15%, p<0.0001). During the 24-week double-blind treatment period, sovleplenib demonstrated superior efficacy across several key metrics; specifically, the overall response rate—defined as hemoglobin (Hb) ≥100 g/L with an increase of ≥20 g/L from baseline without rescue therapy—was significantly increased (70% vs 22%, p<0.0001). The use of protocol-defined rescue therapy was significantly reduced with sovleplenib (16% vs 54%, p=0.0001), fewer patients received red blood cell transfusion (11% vs 43%) and higher patients with tapering or discontinuation of glucocorticoids or other baseline concomitant anti-wAIHA therapies (50% vs 15%, p=0.003​).

Median time to response was 3.1 weeks for sovleplenib versus 6.3 weeks for placebo, while the median cumulative duration of response among overall responders was 16.1 versus 6.1 weeks, respectively. Additionally, an improvement in hemolytic markers was observed with sovleplenib compared with placebo, showing an alleviation of active hemolysis.

These efficacy findings remained consistent across all sensitivity analyses, and all subgroup analyses further supported the primary endpoint results. Notably, in patients who had received prior rituximab therapy, the durable response rate continued to favor sovleplenib over placebo (69% vs 16%, p=0.0022).

Sovleplenib demonstrated a favorable safety profile. Grade ≥3 treatment-emergent adverse events ("TEAE") were reported in 43% patients in the sovleplenib arm and 59% patients in the placebo arm. The most common Grade ≥3 TEAEs, occurring in at least 10% of patients, were warm autoimmune hemolytic anemia (18% vs 43%) and upper respiratory tract infection (2% vs 11%). There were no TEAE-related deaths or treatment discontinuations reported in the sovleplenib group.

Details of the presentation are as follows:

Title:

A randomized, double-blind, placebo-controlled Phase 3 study of ESLIM-02 for efficacy and safety of sovleplenib (HMPL-523) in patients with warm autoimmune hemolytic anemia in China

Lead Author:

Bing Han, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China

Session:

Oral Session (Targeted therapies in rare red cell and metabolic disorders)

Presentation ID:

S301

Date & Time:

Thursday, 11 June 2026, 17:00 CEST

Location:

A13 Hall

About Sovleplenib and wAIHA

Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.

The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc-gamma receptor (FcγR) bearing macrophages is thought to be the pathogenic mechanism in wAIHA.1 Activated Syk mediates downstream signaling of the activated Fc receptors in phagocytic cells, resulting in phagocytosis of RBCs.2 In addition, activation of Syk through the B-cell receptor mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells.3 Inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production.

In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia ("ITP"). Positive results from ESLIM-01 (NCT05029635), a Phase III trial in China of sovleplenib in patients with primary ITP, have been published in The Lancet Haematology. The NMPA accepted for review the resubmitted NDA filing for the treatment of ITP and granted it priority review in February 2026. According to IQVIA, China has 430,000 existing patients with 41,000 new ITP patients each year. About half of ITP patients fail to have satisfactory results from currently approved treatments such as TPO (thrombopoietin) / TPO-RAs (thrombopoietin receptor agonists).

HUTCHMED currently retains all rights to sovleplenib worldwide.

(Press release, Hutchison China MediTech, JUN 12, 2026, View Source [SID1234666602])

On June 11, 2026 Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, reported that the first patient has been dosed in QUATRO-APL, the company’s global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing the first patient in QUATRO-APL is an important clinical development milestone for Quetzal," said Usman Ahmed, Chief Executive Officer and Chairman of Quetzal Therapeutics. "We look forward to continued enrollment and to working with our investigators, clinical sites, and partners as the trial progresses."

"Current standard-of-care regimens for APL require a significant number of intravenous infusions over the course of therapy, which can be burdensome for patients and healthcare systems," said Shaad Abedin, M.D., Chief Medical Officer of Quetzal Therapeutics. "QUATRO-APL is designed to evaluate whether an oral formulation of arsenic trioxide can offer a potential alternative to intravenous administration. We are grateful to the investigators, site teams, and partners whose commitment made this milestone possible."

Quetzal Therapeutics expects continued site activation and patient enrollment across the United States and Europe as the global Phase 3 program advances and plans to provide additional updates on study progress as enrollment continues.

About the QUATRO-APL Trial

QUATRO-APL (QTX-2101-301) is a pivotal, open-label Phase 3 clinical study evaluating the efficacy, safety, and pharmacokinetics of QTX-2101, an oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), in adult patients with newly diagnosed, low-risk acute promyelocytic leukemia. The comparator arm is intravenous arsenic trioxide plus ATRA.

Additional information is available at ClinicalTrials.gov (NCT07504458) and the EU Clinical Trials Information System (2025-524810-28-00).

About Acute Promyelocytic Leukemia

APL is a rare and aggressive subtype of acute myeloid leukemia, accounting for approximately 10-15% of all AML cases. It is defined by the PML-RARA gene fusion and is associated with severe bleeding complications and rapid disease progression if untreated. While advances in therapy have transformed outcomes, current treatments often require patients to undergo a large number of lengthy intravenous infusions over the course of therapy. This relentless treatment schedule can disrupt daily life and place a significant burden on both patients and their support networks. There remains a clear need for innovative and more accessible therapies.

(Press release, Quetzal Therapeutics, JUN 11, 2026, View Source [SID1234666604])

On June 11, 2026 Parabilis Medicines, Inc. (Nasdaq: PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, reported the closing of its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 5,025,000 additional shares, at an initial public offering price of $20.00 per share. All of the shares of common stock were offered by Parabilis. Parabilis’ common stock began trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol "PBLS".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leerink Partners, BofA Securities, Evercore ISI and Guggenheim Securities acted as active book-running managers for the offering. LifeSci Capital acted as a passive bookrunning manager for the offering.

In addition to the shares sold in the initial public offering, Parabilis reported the closing on June 11, 2026, of its sale of 4,166,666 shares of common stock at $18.00 per share, or 90% of the initial public offering price per share, in a concurrent private placement to Regeneron Pharmaceuticals, Inc. The sale of the shares of common stock in the concurrent private placement was not registered under the Securities Act of 1933, as amended.

The gross proceeds to Parabilis from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions, and offering expenses payable by Parabilis, were $770.5 million. In addition, Parabilis received proceeds of approximately $75 million from the sale of shares of common stock in the concurrent private placement. All of the shares of common stock were offered by Parabilis.

In connection with the initial public offering, all Parabilis preferred stock converted into common stock, and a $50 million Simple Agreement for Future Equity ("SAFE") held by Explore Investments LLC converted into common stock.

Parabilis has raised over $1.2 billion in funding (before fees and expenses) in 2026, across public and private financings and strategic collaborations, to support its mission to create extraordinary medicines for patients.

Registration statements relating to the initial public offering have been filed with the Securities and Exchange Commission (the "SEC") and became effective on June 9, 2026. The offering was made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus may be obtained from the SEC’s website at www.sec.gov or from: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: 1-800-808-7525, email: [email protected]; BofA Securities, Inc., Attn: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255-0001, email: [email protected]; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, telephone: (888) 474-0200, email: [email protected]; or Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, telephone: (212) 518-9544, email: [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Parabilis Medicines, JUN 11, 2026, View Source [SID1234666601])

On June 11, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, reported the issuance of two new U.S. patents and the allowance of an additional U.S. patent application covering its proprietary IL-4 and IL-13 Superkine platforms, including bizaxofusp (formerly MDNA55), the Company’s IL-4 Empowered Superkine in clinical development for recurrent glioblastoma (rGBM).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The newly issued U.S. patents, together with parallel patents recently granted in Australia and Canada within the same patent families, further reinforce Medicenna’s intellectual property position across the cytokine biology underlying its lead clinical programs: bizaxofusp, MDNA11 (IL-2 Superkine) and MDNA113 (anti–PD-1 × IL-2 bifunctional Superkine).

"These newly issued and allowed U.S. patents underscore the depth and breadth of the Superkine science Medicenna has built and the strength of the IP estate now protecting the platforms behind bizaxofusp, MDNA11 and MDNA113," said Dr. Fahar Merchant, President and Chief Executive Officer of Medicenna. "Our cytokine engineering work spans three distinct receptor systems, including IL-2, IL-4 and IL-13 and these grants extend protection into important new applications, including cellular immunotherapy and combination treatment of CNS tumors. With more than 100 active granted patents and applications worldwide, Medicenna has assembled what we believe is one of the most comprehensive patent estates in Superkine-based immunotherapy."

U.S. Patents Recently Issued

U.S. Patent No. 12,503,496: "Interleukin-4 Receptor-Binding Fusion Proteins and Uses Thereof" (Medicenna and the U.S. National Institutes of Health, co-owners). The issued patent covers the application of Medicenna’s proprietary IL-4 Superkine fusion proteins to enhancing cellular immunotherapy. With this grant, the family now includes three issued U.S. patents, and additional granted patents in Europe and India.
U.S. Patent No. 12,590,133: "IL-13/IL-4 Superkines: Immune Cell Targeting Constructs and Methods of Use Thereof" (in-licensed by Medicenna from Stanford University). The issued patent is directed to IL-13 Superkine immune cell targeting constructs, vectors, and engineered cells. The family is now granted in the United States and China, with pending applications in Canada and Europe.
U.S. Patent Recently Allowed

U.S. Patent Application No. 18/248,601: "Combination Therapy of MDNA55 and a Vascular Endothelial Growth Factor a (VEGF-A)" (Medicenna-owned). Once issued, the patent will cover combinatorial treatment of CNS tumors with bizaxofusp, including with VEGF-A-directed agents. The family also has pending applications in Canada, China, Europe, India, Japan and Korea.
Additional Recent Patent Grants Outside the United States

In parallel with these U.S. milestones, Medicenna recently received patent grants in two additional jurisdictions that extend the geographic reach of its core Superkine families:

Australian Patent No. 2018347796, "IL-4 Fusion Formulations for Treatment of Central Nervous System (CNS) Tumors," directed to Medicenna’s proprietary bizaxofusp formulation and its application to the treatment of CNS tumors. This family is now granted in Australia, Europe and the United States, with pending applications in Canada, China and India.
Canadian Patent No. 3,067,909, "Uses and Methods for IL-2 Superagonists, Agonists, and Fusions Thereof," directed to the combination of Medicenna’s IL-2 Super Agonist and checkpoint inhibitors for the treatment of cancer. This family is now granted in Australia, Canada, Japan and the United States, with additional pending applications in China, Europe and India, as well as further applications in Australia, Japan and the United States.
Medicenna continues to develop a robust global patent portfolio across its R&D platforms and clinical programs, with over 100 active granted patents and applications.

(Press release, Medicenna Therapeutics, JUN 11, 2026, View Source [SID1234666599])

On June 11, 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) reported that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy in stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer, a type of tumour characterised by high mutation rates. The FDA has granted Priority Review and is expected to make a decision on the approval by 9 October 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This filing acceptance brings us closer to establishing adjuvant Tecentriq plus chemotherapy as a new standard of care for certain types of early colon cancer," said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. "The ATOMIC results demonstrate that Tecentriq plus chemotherapy can substantially reduce the risk of disease recurrence or death, helping more patients remain cancer-free following surgery."

"One in three patients with stage III colon cancer will relapse within five years, underscoring the need for new adjuvant treatment options," said Michael Sapienza, CEO, Colorectal Cancer Alliance. "This milestone represents a critical step toward a reality where treatment is tailored to a patient’s specific tumor biology from the very beginning, giving them a better chance of preventing a recurrence."

The application is based on the landmark ATOMIC study, recently published in The New England Journal of Medicine. ATOMIC demonstrated that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50%, compared to chemotherapy alone for people with stage III dMMR colon cancer, determined by an immunohistochemistry test, such as the VENTANA MMR RxDx Panel. The 36-month disease-free survival was 86% for Tecentriq combined with FOLFOX6 compared with 76% in the FOLFOX6 alone group. The safety profile was consistent with previous studies of Tecentriq and FOLFOX6.1

Colon cancer remains one of the world’s most common and deadliest tumours.4 Over one million people are diagnosed globally each year, and despite surgery and chemotherapy, approximately 30% of stage III patients relapse within five years.2-4 Approximately 15% of colon cancer patients present with dMMR/MSI-H tumours, which indicate a higher mutation rate and thus have the potential to respond to immunotherapy.5

Roche is pursuing further regulatory filings for Tecentriq, including with the European Medicines Agency, to bring this first immunotherapy-based adjuvant option to patients with dMMR/MSI-H colon cancer worldwide.

The ATOMIC study was sponsored by the National Cancer Institute (NCI) and conducted by the Alliance for Clinical Trials in Oncology in partnership with Roche and the Arbeitsgemeinschaft Internistische Onkologie (AIO) group in Germany. It highlights Roche’s commitment to working alongside leading academic groups to tackle some of the most challenging cancers.

About the ATOMIC study
ATOMIC (A021502, NCT02912559) is a phase III, randomised, open-label, multicentre study investigating the addition of Tecentriq (atezolizumab) to FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomised 1:1 to receive either FOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or FOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS).

About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations.

(Press release, Hoffmann-La Roche, JUN 11, 2026, View Source [SID1234666598])